PDCD1 and non-small cell lung carcinoma: One of these reported that an early elevation in CRP and/or systemic IL-6 within 7 days following administration of PD-1/PD-L1 inhibitors (nivolumab/pembrolizumab) to 31 evaluable patients with NSCLC “was indicated to be predictive of therapeutic efficacy” (64).